BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.97B

Market cap10.97B

Price-Earnings ratio

148.67

Price-Earnings ratio148.67

Dividend yield

—

Dividend yield—

Average volume

2.46M

Average volume2.46M

High today

$57.58

High today$57.58

Low today

$55.40

Low today$55.40

Open price

$56.43

Open price$56.43

Volume

698.14K

Volume698.14K

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

BioMarin(BMRN) stock is priced at $56.68, giving the company a market capitalization of 10.97B. It carries a P/E multiple of 148.67.

On 2026-10-15, BioMarin(BMRN) stock traded between a low of $55.40 and a high of $57.58. Shares are currently priced at $56.68, which is +2.3% above the low and -1.6% below the high.

BioMarin(BMRN) shares are trading with a volume of 698.14K, against a daily average of 2.46M.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $70.98 and a 52-week low of $49.26.

BMRN News

TipRanks 15h

BioMarin assumed with a Buy at UBS

UBS analyst Joon Lee assumed coverage of BioMarin (BMRN) with a Buy rating and $88 price target The firm views the company as a turnaround story. Management cha...

TipRanks 1d

BioMarin price target raised to $114 from $111 at Barclays

Barclays raised the firm’s price target on BioMarin (BMRN) to $114 from $111 and keeps an Overweight rating on the shares as part of a Q3 earnings preview. BioM...

Simply Wall St 3d

What BioMarin Shares New VOXZOGO Data Means For Shareholders

BioMarin Pharmaceutical reported extensive new clinical data across VOXZOGO and its skeletal pipeline, regulatory progress on a hypochondroplasia sNDA, and long...

Analyst ratings

77%

of 31 ratings

Buy

77.4%

Hold

22.6%

Sell

More BMRN News

Simply Wall St 7d

Is BioMarin Pharmaceutical Below Fair Value After New Clinical Data And Its AI Deal?

Fresh clinical data and an AI drug discovery deal have pushed BioMarin Pharmaceutical (BMRN) back into focus, as investors weigh what the latest Pompe and Duche...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.